Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

785 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF. Bengala C, et al. Among authors: conte pf. Ann Oncol. 2001 Jan;12(1):69-74. doi: 10.1023/a:1008302402687. Ann Oncol. 2001. PMID: 11249051 Free article. Clinical Trial.
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O, Puccini G, Pisani P, Poli M, Dani D, Landucci E, Mariani G, Conte PF. Gennari A, et al. Among authors: conte pf. Clin Breast Cancer. 2000 Jul;1(2):156-61; discussion 162-3. doi: 10.3816/cbc.2000.n.014. Clin Breast Cancer. 2000. PMID: 11899654
Role of epirubicin in advanced breast cancer.
Conte PF, Gennari A, Landucci E, Orlandini C. Conte PF, et al. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S46-51. doi: 10.3816/cbc.2000.s.009. Clin Breast Cancer. 2000. PMID: 11970749 Review.
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Gennari A, et al. Clin Breast Cancer. 2002 Dec;3(5):346-52. doi: 10.3816/CBC.2002.n.038. Clin Breast Cancer. 2002. PMID: 12533265 Clinical Trial.
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF. Baldini E, et al. Among authors: conte pf. Ann Oncol. 2003 Feb;14(2):227-32. doi: 10.1093/annonc/mdg069. Ann Oncol. 2003. PMID: 12562649 Free article. Clinical Trial.
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. Bengala C, et al. Among authors: conte pf. Bone Marrow Transplant. 2003 Feb;31(4):275-80. doi: 10.1038/sj.bmt.1703827. Bone Marrow Transplant. 2003. PMID: 12621462
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF. Cappuzzo F, et al. Among authors: conte pf. Br J Cancer. 2004 Jan 12;90(1):31-5. doi: 10.1038/sj.bjc.6601518. Br J Cancer. 2004. PMID: 14710202 Free PMC article. Clinical Trial.
785 results